The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 24, 2020

Filed:

Mar. 19, 2017
Applicant:

Exuma Biotech Corp., West Palm Beach, FL (US);

Inventors:

Gregory Ian Frost, West Palm Beach, FL (US);

James Joseph Onuffer, Alameda, CA (US);

Ghiabe H. Guibinga, San Diego, CA (US);

Assignee:

Exuma Biotech Corp., West Palm Beach, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/115 (2010.01); A61K 48/00 (2006.01); C12N 15/113 (2010.01); C12N 15/63 (2006.01); C12N 15/87 (2006.01); C12N 15/11 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C12N 5/0783 (2010.01); C12N 15/10 (2006.01); A61K 35/17 (2015.01); C07K 14/005 (2006.01); C07K 14/54 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0066 (2013.01); A61K 35/17 (2013.01); C07K 14/005 (2013.01); C07K 14/5418 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 14/715 (2013.01); C07K 14/7155 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2863 (2013.01); C07K 16/30 (2013.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); C12N 7/00 (2013.01); C12N 15/1048 (2013.01); C12N 15/113 (2013.01); C12N 15/635 (2013.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/31 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01); C12N 2310/141 (2013.01); C12N 2510/00 (2013.01); C12N 2740/15021 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/15052 (2013.01); C12N 2740/16043 (2013.01); C12N 2740/16045 (2013.01); C12N 2760/18422 (2013.01); C12N 2830/002 (2013.01);
Abstract

The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells without prior ex vivo stimulation. The methods typically include engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted CAR. Additional elements of such engineered signaling polypeptides are provided herein, as well as vectors, such as retroviral vectors, packaging cell lines and methods of making the same. Furthermore, recombinant retroviruses and methods of making the same are provided. Numerous controls are provided, including riboswitches that are controlled, for example in vivo, by nucleoside analogues.


Find Patent Forward Citations

Loading…